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INTRODUCTION
Chronic wounds are characterized by repeated tissue 
injury, ischemia, and elevated bacterial burden, all of which 
combine to result in continued inflammation and an imbal-
ance in tissue proteases and inhibitors.1–3 Chronic wounds, 
such as diabetic foot ulcers, venous leg ulcers, and pressure 
ulcers, lead to a significant burden on patient quality of life 
and healthcare cost.4–9 An administrative claims study showed 
that 15% of Medicare beneficiaries are affected by chronic 
wounds, with an estimated annual cost of $28 billion.10
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Background: Chronic wounds represent a significant financial burden to the 
healthcare system and a quality-of-life burden to patients. Many chronic wounds 
have elevated bioburden in the form of biofilm, which has been associated with 
delayed wound healing. This study examined the use of a native type I collagen ma-
trix with the antimicrobial polyhexamethylene biguanide (PCMP) in the manage-
ment of bioburden and treatment of chronic, nonhealing wounds over 12 weeks.
Methods: A prospective case series of PCMP enrolled adults ≥18 years old with a 
nonhealing wound. At week 0, the wound was prepared by sharp or mechanical 
debridement. Patients received standard wound care plus PCMP applications at 
week 0 and then weekly up to week 12 at the investigator’s discretion. Dressings 
were applied over PCMP to fix it in place. At each visit, wounds were assessed for 
the extent of healing and signs of wound infection.
Results: Of the 41 wounds studied, 44% were pressure ulcers, 22% were surgical 
wounds, 12% were venous ulcers, 10% were diabetic ulcers, and 12% were another 
type. The median (interquartile range) baseline wound area was 7.2 (14.9) cm2, 
and the mean wound duration was 103 weeks. Of the 41 wounds, 73% demon-
strated a reduction in wound area at 12 weeks, and 37% achieved complete wound 
closure, with a mean time of 6.7 weeks to complete closure.
Conclusion: PCMP treatment appeared to positively impact the course of 
wound healing in a variety of complex, chronic wounds that were unrespon-
sive to prior treatment. (Plast Reconstr Surg Glob Open 2019;7:e2047; doi: 10.1097/
GOX.0000000000002047; Published online 15 January 2019.)
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The elevated bioburden in chronic wounds is often 
in the form of biofilm.11 Biofilm occurs when planktonic 
(free-floating) bacteria adhere to a solid surface, prolif-
erate, and exude substances to form a polymeric matrix 
enclosing a monomicrobial or polymicrobial communi-
ty.12,13 Approximately 10–20% of the biofilm is composed 
of microorganisms and 80–90% is composed of extracel-
lular polymeric matrix.14 In 2010, there were an estimated 
17 million biofilm-associated disease cases in the United 
States, with direct costs of approximately $94 billion.15 
Chronic wounds with a large quantity of slough may be at 
an increased risk of developing pathogenic and antimicro-
bial-resistant biofilms.14 Emerging evidence indicates that 
the presence of biofilm is associated with delayed wound 
healing.16–18 Compared with planktonic bacteria, bacteria 
in biofilms are more difficult to eradicate using topical or 
systemic antibiotics.13,19,20
Debridement of a chronic wound is the first step to 
disrupting a pathogenic biofilm and removing necrotic 
tissue, both of which contribute to delayed wound heal-
ing.14,21 However, debridement is not sufficient by itself. 
Recent research has shown that clinic-based debridement 
of chronic ulcers has minimal effect on surface bacterial 
counts.22 Topical antiseptics and antimicrobials can be ap-
plied after debridement to reduce the bacterial count and 
assist in wound healing.23,24 Historical options for wound 
antimicrobial treatment include silver, honey, iodine, or 
chlorhexidine. However, questions remain about the ef-
ficacy and safety of these agents when they are applied in 
dressings.24,25
Polyhexamethylene biguanide hydrochloride (PHMB) 
is a cationic topical antimicrobial that strongly binds to bac-
terial cell walls and membranes, disrupting the transport, 
biosynthesis, and catabolic functions of the bacterium.26,27 
PHMB possesses broad antimicrobial activity against 
Gram-positive and Gram-negative bacteria, plaque- and 
biofilm-forming bacteria, and intracellular bacteria such as 
Chlamydiae and Mycoplasma.27 In addition, PHMB binds to 
biofilm matrix components and increases in concentration 
during application, thereby creating an increasingly toxic 
environment for bacteria.28 PHMB does not seem to be af-
fected by multidrug efflux pumps or acquired resistance 
developed by bacteria.26,27 It is regarded as a very biocom-
patible antiseptic that shows little-to-no toxicity or systemic 
uptake when applied on intact skin or wounds.27,29 A recent 
systematic review demonstrated that use of PHMB dressings 
was associated with faster and more substantial reductions 
in bacterial counts, including multidrug-resistant species, 
than control dressings.30 A study of PHMB dressings used in 
wounds with biofilm showed positive outcomes for wound 
disinfection and patient-reported pain.31
Collagen matrices can serve as a sacrificial surface for 
matrix metalloproteinases and elastase that are prevalent 
in chronic wounds, thus protecting tissue collagen deposi-
tion.32 Retaining the native collagen matrix structure sup-
ports healing and has been shown to effectively address 
the protease imbalance seen in chronic wounds, and sup-
port granulation tissue formation and epithelialization.33 
Collagen matrices can sequester proteolytic enzymes and 
act as a biocompatible scaffold to support healing.34
Here, we propose using native type I porcine-derived 
collagen matrix coated with 0.1% PHMB (porcine col-
lagen matrix with PHMB, further referenced as PCMP). 
PCMP is a Food and Drug Administration Class II Medi-
cal Device 510(k) cleared #K051647 and intended for the 
management of wounds, as an effective barrier to resist 
microbial colonization within the dressing and reduce 
microbes penetrating through the dressing. PCMP is the 
only dressing available in the United States with the com-
bination of native collagen matrix and PHMB. It is sup-
plied dry in sheet form and packaged in sterile, sealed 
single patches.35
The aim of this study was to assess the ability of PCMP 
to meet wound-specific treatment goals including manage-
ment of bioburden, support of granulation tissue forma-
tion, and support of wound closure over a 12-week period 
in chronic, nonhealing wounds of various etiologies.
METHODS
Study Design
A single-center, prospective, case series of PCMP (Pura-
Ply Antimicrobial, Organogenesis Inc., Canton, Mass.) was 
conducted (NCT03070925). The study was approved by 
Biomedical Research Alliance of New York, IRB #16-08-
209-03, and was conducted in accordance with current 
International Council for Harmonisation and Good Clini-
cal Practice guidelines. All patients provided their writ-
ten informed consent to participate in the study. Eligible 
wounds were evaluated weekly for up to 12 weeks for size, 
healing, and improvement in granulation tissue.
Participants
Adults ≥18 years of age with at least 1 appropriate 
wound (including partial- and full-thickness wounds, pres-
sure ulcers, venous leg ulcers, diabetic foot ulcers, chronic 
vascular ulcers, surgical wounds, or trauma wounds) were 
eligible for inclusion. Individuals were excluded from par-
ticipating if they were receiving concurrent treatment with 
other topical antimicrobials or skin substitute products, or 
if they had a third-degree burn or a known sensitivity to 
any of the PCMP materials.
Procedures
Eligible patients with an identified target wound under-
went clinical assessments and received standard of care as 
determined by the treating physician. The treating physi-
cian determined the frequency and type of assessments per-
formed for each patient, according to standard of care for 
their target wound and the patient’s individualized needs 
for treatment and follow-up. Data were collected at every 
clinical visit in which PCMP was applied to the target wound 
and at postapplication follow-up visits as appropriate.
Wounds were cleaned and prepared with sharp de-
bridement or mechanical debridement at the initial visit. 
After preparation, PCMP was applied at week 0 to the 
study wound. Each PCMP sheet was on the wound for a 
minimum of 1 week and a maximum of 3 weeks. In moist 
wounds, when PCMP was applied; no saline was needed 
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to moisten the product. It was fixated with nonadherent 
dressing (CONFORMANT 2; Smith & Nephew, Largo, 
Fla.) and secured at the edges with steri-strips or strips 
of retention dressing (Hypafix; Smith & Nephew). The 
nonadherent dressing allowed the wound to drain. Foam 
dressing (Allevyn; Smith & Nephew) was placed over the 
nonadherent dressing. Gauze and stretch bandage were 
applied to fix all the dressings in place. For drier wounds, 
saline-moistened PCMP was covered with nonadherent 
dressing, and secured at the edges with steri-strips or strips 
of retention dressing. Gauze and stretch bandage were ap-
plied to fix the dressings and PCMP in place. The outer 
dressings could be changed within 1 week, if needed, with-
out disturbing the PCMP and the nonadherent dressing.
Assessments
At each clinic visit, wounds were assessed for the extent 
of healing and any signs of wound infection. Wound mea-
surements included wound area and depth, and achieve-
ment of complete wound closure (Yes/No). Photographs 
were taken before PCMP application, before removal of 
the PCMP, after debridement, after placement of a new 
PCMP, and, if it occurred, upon healing.
Statistical Analysis
All analyses were performed on patients who received 
PCMP treatment (intent-to-treat population). Descriptive 
statistics (eg, mean, SD, median) were calculated with 
Microsoft Excel 2016 (version 16.0.9330.2124) for demo-
graphic and baseline characteristics, the time to wound 
closure, the change in wound surface area from baseline 
to week 12, and the percent wound closure from base-
line to week 4 or 12. The Wilcoxon signed rank test was 
performed (Microsoft Excel 2016) to examine whether 
the wound area at week 12 was significantly different (at 
α = 0.05) from the baseline area. No patient showed signs 
of complications or infection at the conclusion of the 
study.
RESULTS
A total of 41 wounds (1 wound per participant) were 
included in the analysis. The mean (SD) age of partici-
pants was 61.9 (14.1) years and 65.9% (27/41) were male 
(Table 1). At baseline, 18 of 41 (43.9%) of the wounds 
were pressure ulcers, 9/41 (22.0%) were surgical wounds, 
5/41 (12.2%) were venous leg ulcers, 4/41 (9.8%) were 
diabetic foot ulcers, and 5/41 (12.2%) were another type 
of wound. The median (interquartile range) baseline 
wound area was 7.2 (14.9) cm2, and the mean (SD) depth 
was 0.58 (0.64) mm. The mean wound duration before 
PCMP application was 103.1 weeks (n = 41).
The anatomical locations of patient wounds varied. 
Wounds were located on the foot (n = 19), ankle (n = 5), 
anterior leg (n = 5), toe (n = 3), heel (n = 2), sacrum 
(n = 2), ischium (n = 2), and 1 each on the thigh, breast, 
knee, and posterior leg.
There was a vast array of comorbidities present within 
the cohort; however, certain ailments were represented 
heavily. Hypertension was present in 28 patients, type 2 
diabetes mellitus in 22, hyperlipidemia in 15, peripheral 
vascular disease in 13, coronary artery disease in 11, and 
chronic kidney disease in 9 patients.
Before participating in the study, 16 (38.1%) patients 
underwent compression therapy, 27 (64.3%) had at-
tempted off-loading, 42 (97.7%) patients had the target 
wound debrided at least once before starting the study, 
10 (23.8%) patients used negative pressure therapy, 10 
(23.8%) underwent hyperbaric oxygen therapy, 7 (17.1%) 
patients had an amputation performed due their wound, 
7 (17.1%) attempted surgical closure of their wounds, 12 
(29.3%) patients were treated with skin substitutes, and 
13 (34.2%) used topical antimicrobials on their wounds.
PCMP is typically applied on a weekly basis according 
to standard of care and the patient’s individualized needs 
for treatment and follow-up. For a few patients in this 
study, PCMP was left in place for 2–3 weeks. At the week 
1 follow-up visit after PCMP application, the usual course 
of action is to remove the PCMP and reapply. However, 
in these few patients, the PCMP was found to be dry and 
stuck to the wound at the follow-up. Rather than remove 
the PCMP and potentially open the wound, the PCMP was 
left in place until a subsequent visit, at which point it had 
either integrated into the wound or could lift off easily, 
revealing a healed wound.
The 41 wounds in this study received an average of 8 
PCMP applications each. During this study, 2/41 patients 
received adjunctive therapy of hyperbaric oxygen treat-
ments; both patients had pressure ulcers that had been 
present for over 1 year before study entry and had prior 
hyperbaric oxygen treatments for the study wound. Of the 
41 wounds, 30 (73.2%) demonstrated an overall reduction 
in wound area over the 12-week study and 15/41 (36.6%) 
achieved complete wound closure (Fig. 1). Of the wounds 
achieving complete closure, the mean (SD) time to closure 
was 6.7 (3.0) weeks. By wound type, 7/18 (38.9%) of pres-
sure ulcers, 5/9 (55.6%) of surgical wounds, 1/1 (100%) 
of trauma wounds, 1/4 (25%) of diabetic foot ulcers, 
and 1/5 (20%) of venous leg ulcers achieved complete 
closure. Mean wound closure by wound type is shown in 
Table 2. Of the 30 wounds that showed a decrease in area, 
26 had decreased by ≥70% from baseline to week 12. After 
12 weeks, the median decrease in wound area was 3.1 cm2 
and the mean (SD) was 7.5 (11.2) cm2 (Fig. 2). When a 
Table 1. Demographic and Baseline Characteristics
Characteristics
ITT Population 
(n = 41)
Age (y), mean (SD) 61.9 (14.1)
Sex, n (%)  
  Female 14 (34.1)
  Male 27 (65.9)
Race, n (%)  
  White 27 (65.9)
  Black 5 (12.2)
  Asian 2 (4.9)
  Other 7 (17)
Baseline wound area (cm2), mean (SD) 18.0 (36.1)
Median 7.2
Range 0.3, 218.5
Baseline wound depth (mm), mean (SD) 0.58 (0.64)
ITT, intent-to-treat.
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paired Wilcoxon signed rank test is performed, the wound 
area at week 12 was significantly different from baseline 
(P < 0.001). Wounds also visibly had an increase in granu-
lation tissue with healing. Five wounds increased in size 
from baseline to week 12 due to patient noncompliance.
One participant died during the study period due to 
a comorbid condition. No wounds showed signs of com-
plications or infection after 12 weeks, and there were no 
reports of adverse events attributable to PCMP.
DISCUSSION
This study of PCMP represents an extensive case  series 
of a native type I collagen matrix with PHMB antimicrobial 
for the management of chronic, nonhealing skin wounds. 
The application of PCMP appeared to positively impact 
the course of wound healing in a variety of complex, 
chronic wounds that were unresponsive to prior treat-
ment, and in many cases even resulted in wound closure.
At 12 weeks, most (73.2%) wounds reduced in area 
from baseline and many (63.4%) had reached a ≥70% re-
duction in area. Complete closure was achieved in many 
types of wounds, including surgical and trauma wounds, 
pressure ulcers, diabetic foot ulcers, and venous leg ul-
cers. The time to complete wound closure was relatively 
Fig. 1. Photographs show wound healing progress after PCMP application. A–C, A venous leg ulcer with a baseline wound area of 19.5 cm2 
had been present for 4 months. Previously, the patient underwent compression, debridement, and collagenase treatments. The patient re-
ceived 11 applications of PCMP. D–F, A surgical wound with baseline wound area of 21.4 cm2 had been present for 1 month. The patient un-
derwent off-loading, debridement, and negative pressure therapy before study participation. The patient received 9 applications of PCMP.
Table 2. Mean Percent Wound Closure from Baseline, by 
Wound Type
Wound Type, n (%)
Closure at  
Week 4 (%); 
n = 41
Closure at  
Week 12 (%); 
n = 35
All wounds 37.2 63.1
Pressure ulcer, 18 (43.9) 31.6 61.1
Surgical wound, 9 (22.0) 52.9 84.7
Venous leg ulcer, 5 (12.2) 44.6 89.3
Diabetic foot ulcer, 4 (9.8) 43.2 50.3
Ischemic wound, 1 (2.4) 63.2 60.5
Trauma wound, 1 (2.4) 93.1 100
Graft-versus-host disease  
wound, 1 (2.4)
0* 70.7
Other, 2 (4.9) 13.4 0†
*The sole graft-versus-host disease wound increased in area from week 0 
(84.5 cm2) to week 4 (168 cm2) and then reduced in size to 24.8 cm2 at week 12.
†One patient had a radiation ulcer that decreased in size from 1.2 cm2 at week 
0 to 0.6 cm2 at week 4, but had no measurement at week 12. The second patient 
had a mixed venous stasis and diabetic neuropathic pressure ulcer that was 
76.7 cm2 at week 0, 94.5 cm2 at week 4, and 77 cm2 at week 12.
Fig. 2. Box and whisker plot of change in wound surface area with 
PCMP application for wounds of baseline area less than 45 cm2. The 
boxes represent the interquartile range, the error bars represent the 
range, and the diamonds represent the mean.
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short (6.7 weeks) relative to the duration of the wounds 
(103 weeks). An earlier case series with PCMP demon-
strated an average time to complete wound closure of 6.8 
weeks.36 PCMP was well tolerated, and no systemic or local-
ized adverse events were reported that were attributed to 
PCMP. Another case series of 9 wounds treated with PCMP 
showed that 6 of the 9 wounds healed in an average of 10 
weeks, with the remaining wounds showing improvements 
in granulation tissue and a reduction in wound area.37
In recent studies of skin substitutes for the treatment of 
wounds, at baseline, venous leg ulcers had a median area 
of 6.0–7.5 cm2 and diabetic foot ulcers had a median area 
of 3.0–3.9 cm2. The median times to wound closure were 
reported as 19.5 weeks for dehydrated human amnion 
chorion membrane (dHACM; EpiFix, MiMedx, Marietta, 
Ga.), 25 weeks for fetal bovine collagen dressing (Prima-
trix, Integra Life Sciences, Waltham, Mass.), and 36 weeks 
for acellular porcine small intestinal submucosa collagen 
dressing (SIS; Oasis, Smith & Nephew, Largo, Fla.).38,39 In 
this prospective study of a variety of wound types in which 
the median baseline wound area was 7.2 cm2, time to 
wound closure with PCMP was 12.9 to 29.4 weeks shorter 
than that reported for other skin substitutes, represent-
ing a 66% to 82% reduction in time to closure. Similarly, 
wound closure rates of other skin substitutes by or at 12 
weeks were 32% for dHACM, 27% for fetal bovine col-
lagen dressing, and 14% for SIS.38,39 In this study, PCMP 
resulted in a 37% wound closure rate.
Reducing the time to complete wound closure could 
substantially reduce the costs associated with chronic 
wound management.10 A registry study of nonheal-
ing wounds showed that the cost of unhealed wounds 
was $4,000 per patient at 6 months, which increased to 
$18,000 per patient at 2 years of wound duration.40 PCMP 
treatment appeared to be beneficial for the wound micro-
bial status as well, as none of the chronic wounds in this 
study showed signs of infection at week 12.
Native extracellular matrix is a potent inhibitor of pro-
teases, which are implicated in the dysfunctional healing 
process of chronic wounds.3,34 Native collagen has been 
found to inhibit elastase, resulting in a positive effect on 
wound healing.34 In addition, PHMB is a barrier against 
microbial colonization and biofilm formation.41 The use 
of PCMP appeared to positively affect the number of 
wounds with complete closure and the rate of closure 
compared with the wound history and other literature, 
which could potentially reduce the total cost of wound 
care. For example, PCMP may have reduced the need for 
other, more expensive, wound healing treatments such 
as other skin substitutes, surgical procedures, skin flaps, 
or grafts. For those wounds that necessitated further in-
tervention, PCMP assisted in supporting healing and im-
proving granulation tissue. PCMP could also reduce the 
number of office visits needed to achieve complete wound 
closure, likely reducing associated healthcare costs.
All skin wounds show bacterial colonization, and some 
may even progress to active infection of the superficial, 
deep dermal, or underlying tissues extending through to 
muscle, tendon, capsule, or bone. Persistent, nonhealing 
wounds are likely to be deep, large, and poorly vascular-
ized, with significant necrotic tissue, which pose the great-
est risk for high bacterial counts and biofilm reformation. 
The use of PCMP represents a novel approach for manag-
ing bioburden, thus controlling biofilm formation, while 
neutralizing destructive enzymes and providing a biocom-
patible extracellular matrix to support wound closure.
This study included a relatively small number of wounds, 
so it is difficult to make conclusive statements about closure 
rates or comparisons of closure success for different wound 
types. The study involved a variety of wound types and there 
were few surgical wounds or pressure wounds examined. 
PCMP was also not compared with a control standard-of-care 
group. There was no attempt to randomize patients to differ-
ent treatment arms and the individuals who were assessing 
the wound healing were not blinded to the treatment.
CONCLUSIONS
PCMP represents a new class of wound management 
tools and is comprised of both native type I collagen and 
the antimicrobial PHMB. PCMP appeared to positively im-
pact the management of wound healing across a variety 
of complex chronic wounds. Results need to be further 
explored and validated with randomized, controlled stud-
ies in a larger sample of patients.
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Northwell Health Department of Surgery
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